Abstract

The present invention provides a method whereby carbon dioxide can be efficiently fixed and calcium carbonate, which is a valuable, can be efficiently produced from the carbon dioxide, and whereby waste gypsum boards can be effectively utilized for fixing carbon dioxide without being discarded. This method comprises a first step, in which a first solution, which contains an alkali metal hydroxide, is brought into contact with a gas including carbon dioxide to thereby yield a second solution, which contains an alkali metal salt, and a second step, in which the second solution is brought into contact with a gypsum-containing substance to thereby yield calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B01D 53/62 - Carbon oxides
• B01D 53/75 - Multi-step processes
• B01D 53/78 - Liquid phase processes with gas-liquid contact

Abstract

Provided are a calcium carbonate generation method and a system that make it possible to use calcium-containing waste to generate high-purity calcium carbonate.?According to the present invention, a calcium carbonate generation method that generates calcium carbonate from calcium-containing waste is characterized by having a calcium dissolution step for adding aqueous hydrochloric acid to the calcium-containing waste to dissolve the calcium and generate an aqueous solution that includes calcium ions, a separation step for adjusting a hydrogen ion concentration index for the aqueous solution that includes the calcium ions and separating a component that includes at least one substance selected from the group that consists of Si, Al, Mg, and heavy metals from the aqueous solution, and a calcium carbonate recovery step for using the aqueous solution obtained via the separation step and an aqueous solution that includes potassium carbonate and/or sodium carbonate to generate calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• C01D 7/32 - Purification by dialysis
• C04B 7/60 - Methods for eliminating alkali metals or compounds thereof

Abstract

Provided is a method of pretreating gold ore that allows easily recovering gold and a gold recovery method in which a recovery proportion of gold is high even when the gold ore contains sulfide or a carbonaceous component. The pretreatment method includes a biological oxidation step of bringing the gold ore containing the sulfide into contact with iron oxidizing bacteria and holding them for a predetermined time. The gold recovery method includes: a pretreatment step of pretreating the gold ore by the pretreatment method; a leaching step of leaching the gold from the gold ore to obtain a leaching solution; an adsorption step of adsorbing gold in the leaching solution to activated carbon; and an eluting step of eluting the gold from the activated carbon to obtain a gold solution. Since the sulfide confining the gold particles is oxidatively decomposed by an action of the iron oxidizing bacteria, the gold particles are liberated, thus facilitating the recovery of the gold. As a result, the recovery proportion of the gold can be high.

IPC Classes  ?

• C22B 1/00 - Preliminary treatment of ores or scrap
• C22B 3/04 - Extraction of metal compounds from ores or concentrates by wet processes by leaching
• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins
• C22B 11/00 - Obtaining noble metals

Abstract

[Problem] To provide: a method for simply producing an immunogenic chrysalis for oral administration; and a chrysalis which is for oral administration and produced by said method. [Solution] This method for producing a chrysalis for oral use comprises a step for infecting a larva or chrysalis of a baculovirus infectious insect with a recombinant baculovirus, into which DNA encoding an antigen protein has been introduced, and freeze-drying a chrysalis pupated from the infected larva or the infected chrysalis.

IPC Classes  ?

• A01K 67/033 - Rearing or breeding invertebrates; New breeds of invertebrates
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A61K 35/12 - Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 37/04 - Immunostimulants
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses
• C12N 15/866 - Baculoviral vectors

Abstract

[Problem] To safely and efficiently raise a floating body for a spar-type offshore wind power generation facility by injecting ballast water, at sea. [Solution] A method for raising a floating body 4 for a spar-type offshore wind power generation facility, which is floating sideways, by injecting ballast water at sea, the method comprising: a first step for bringing the floating body 4 for the spar-type offshore wind power generation facility into a state in which the position of center of gravity is made eccentric by a center-of-gravity decentering means; and a second step for raising the floating body 4 for the spar-type offshore wind power generation facility upright by injecting ballast water. The center-of-gravity decentering means can be a weight 2 attached to an outer surface of the floating body 4, or solid ballast 34 put in the floating body 4.

IPC Classes  ?

• B63B 35/00 - Vessels or similar floating structures specially adapted for specific purposes and not otherwise provided for
• F03D 13/25 - Arrangements for mounting or supporting wind motors; Masts or towers for wind motors specially adapted for offshore installation
• B63B 77/10 - Transporting or installing offshore structures on site using buoyancy forces, e.g. using semi-submersible barges, ballasting the structure or transporting of oil-and-gas platforms specially adapted for electric power plants, e.g. wind turbines or tidal turbine generators

Abstract

The present invention provides a compound for treating or preventing diseases caused by excessive mitochondrial divisions. The present invention relates to a compound represented by formula (1) (in the formula: R1 and R1' are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; R2 is optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; R3 and R4 are each independently hydrogen, halogen, hydroxy, nitro, cyano, optionally substituted lower alkyl or the like; R5 and R6 are each independently optionally substituted lower alkyl, optionally substituted lower cycloalkyl, or the like; X is nitrogen or oxygen; Y is carbon, nitrogen, or oxygen; and the broken line represents the presence or absence of a bond), a pharmaceutically acceptable salt or solvate thereof, or a prodrug thereof.

IPC Classes  ?

• A61K 31/4418 - Non-condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 211/90 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
• C07D 213/80 - Acids; Esters in position 3
• C07D 213/82 - Amides; Imides in position 3
• C07D 471/04 - Ortho-condensed systems

Abstract

This membrane protein analysis substrate comprises: an electron microscope grid having a plurality of through holes; a lipid bilayer membrane provided covering at least one of the plurality of through holes; and a membrane protein retained in a portion of the lipid bilayer membrane overlapping in a planar manner with the through holes. The lipid bilayer membrane comprises a lipid monolayer; and the lipid monolayer is larger than the through holes in plan view, adheres to the grid, and constitutes a part of the lipid bilayer membrane.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• H01J 37/20 - Means for supporting or positioning the object or the material; Means for adjusting diaphragms or lenses associated with the support

Abstract

An ionic liquid has a structure represented by the following general formula (1). In the general formula (1), R represents a substituted or unsubstituted alkyl group or a substituted or unsubstituted alkenyl group, and at least one ethylene group comprising the alkenyl group may be substituted with a vinylene group. X+ represents a phospholipid with a cationic group.

IPC Classes  ?

• C07F 9/09 - Esters of phosphoric acids
• C07C 53/08 - Acetic acid
• C07C 53/126 - Acids containing more than four carbon atoms
• C07C 57/12 - Straight chain carboxylic acids containing eighteen carbon atoms

Abstract

Provided is a compound that achieves a good balance between the LO scavenging ability and the LOO* scavenging ability. The compound of die present invention or a salt thereof is represented 5 by the following formula (1):In the formula (1), R1 and R2 may be the same or different and are each independently a hydrogen atom or an alkyl group, R3 is -OR4 or -NHR5, R4 is a sec-butyl group, a tert-butyl group, or an iso¬ butyl group, and R5 is a sec-butyl group, a tert-butyl group, or an iso-butyl group. Compounds of the invention can be used as cell protectant agents, cell growth-promoting agents, or the like.

IPC Classes  ?

• C07C 229/36 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61P 39/06 - Free radical scavengers or antioxidants

Abstract

Provided is an ore dressing method that can efficiently separate copper ore from molybdenum ore. The ore dressing method comprises a conditioning step for adding a disulfite to ore slurry comprising copper ore and molybdenum ore; and, after the conditioning step, an ore flotation step in which ore flotation is performed using the ore slurry. By selectively increasing the hydrophilicity of the copper ore with the disulfite, a difference in hydrophilicity between the copper ore and molybdenum ore can be established. As a result, a selective flotation of the molybdenum ore can be brought about and the copper ore can be efficiently separated from the molybdenum ore.

IPC Classes  ?

• B03D 1/002 - Inorganic compounds
• B03D 1/02 - Froth-flotation processes
• C22B 1/00 - Preliminary treatment of ores or scrap
• C22B 15/00 - Obtaining copper
• C22B 34/34 - Obtaining molybdenum

Abstract

This O-GlcNAcylated protein-like substance contains at least one unit selected from the group consisting of an N-acetylglucosamine unit, carboxy group-containing radical polymerizable units, a styrene unit, a polyethyleneimine unit, a poly-L-lysine unit, and a biotin unit. This fibrosis therapeutic drug contains the O-GlcNAcylated protein-like substance.

IPC Classes  ?

• A61K 31/78 - Polymers containing oxygen of acrylic acid or derivatives thereof
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• C08F 120/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen

Abstract

The present invention provides a pharmaceutical for the prevention and/or treatment of nonischemic cardiomyopathy, said pharmaceutical containing dendritic cells obtained via a method including: a step in which mononuclear cells are cultured in the presence of GM-CSF and IL-2; and a step in which the cultured cells are pulsed with a-Galactosylceramide.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
• C12N 5/0784 - Dendritic cells; Progenitors thereof
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

Provided is a high-performance PPR protein. This PPR protein has more motifs that are linked together than the conventional 7 to 14 motifs and binds to a long base sequence. The PPR motifs are represented by: (A-1) PPR motif comprising a sequence of SEQ ID NO: 9 or 401; (C-1) PPR motif comprising a sequence of SEQ ID NO: 10; (G-1) PPR motif comprising a sequence of SEQ ID NO: 11; and (U-1) PPR motif comprising a sequence of SEQ ID NO:12. These motifs are useful as PPR motifs for, in the order given, adenine, cytosine, guanine, and uracil within a target base sequence.

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 19/00 - Hybrid peptides
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

In order to improve the agglomerating property of PPR protein, A6 amino acid of the first PPR motif (M1) from the N terminus is configured to be more hydrophilic. Further, A9 amino acid of M1 is configured to be a hydrophilic amino acid or glycine. A6 amino acid is preferably asparagine or aspartic acid, and A9 amino acid is preferably glutamine, glutamic acid, lysine, or glycine. Proteins including such PPR motifs as M1 motif have not only an improved agglomerating property but also can have high affinity to a target nucleic acid.

IPC Classes  ?

• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/46 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates
• C07K 19/00 - Hybrid peptides
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/12 - Genes encoding animal proteins
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

A method for producing cells that have been genome edited at a single allele. The method includes a step for introducing (A) and (B) into cells. (A) (a1) Guide RNA to which at least one nucleotide residue has been added at the 5' end of a spacer sequence, (a2) guide RNA that includes a spacer sequence that is mismatched to a target sequence at one or more bases, and/or (a3) an expression vector that causes the guide RNA of (a1) or (a2) to be expressed. (B) The Cas9 protein and/or an expression vector that causes the Cas9 protein to be expressed.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12Q 1/6844 - Nucleic acid amplification reactions
• C12Q 1/6869 - Methods for sequencing
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Abstract

Provided is a compound that is usable as an active ingredient of an anticancer agent. Preferably, provided is a compound that has a DOCK1-inhibiting activity and exerts an anticancer effect based on the activity. A compound represented by formula (A) or a salt thereof: in formula (A), X represents a carbon atom or a nitrogen atom; Y represents an oxygen atom, a hydroxy group or a hydrocarbon group; R1 and R2 are different and represent a hydrogen atom or a group represented by formula (A-1): (in formula (A-1), R6 represents a pyrrolidino group or a phenyl group, and n2 represents 0 or 1) ; R3 represents -CO-R7 (wherein R7 represents an alkoxy group, an alkyl group or an alkylamino group), a 1,3-oxazole group, an alkylhydroxy group, a hydrogen atom or an oxygen atom; R4 represents a hydrogen atom, an oxygen atom or a hydrocarbon group in which a hydrogen atom may be substituted; R5 represents a halogen atom, a halogenated alkyl group or a halogenated alkylthio group; and n1 represents an integer of 0-5.) ; in formula (A), a solid line on the skeleton of the compound represents a single bond, a double line consisting of a solid line and a dotted line represents a single or double bond, and tow dotted lines represent a non-bond or a double bond.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/4439 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• C07D 207/48 - Sulfur atoms
• C07D 233/76 - Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 471/04 - Ortho-condensed systems

Abstract

A disease risk assessment apparatus (100) includes an assessment unit (1) for assessing the risk of developing dementia in a subject, based on the concentration of an amino acid in the blood of the subject. The amino acid includes at least one selected from the group consisting of histidine, phenylalanine, leucine, isoleucine, methionine, threonine, glycine, glutamine, lysine, asparagine, homocysteine, cystathionine, S-adenosylmethionine, and S-adenosylhomocysteine.

IPC Classes  ?

• A61K 31/198 - Alpha-amino acids, e.g. alanine, edetic acid (EDTA)
• A23L 33/175 - Amino acids
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• G01N 33/48 - Biological material, e.g. blood, urine; Haemocytometers

Abstract

Provided is an ore dressing method capable of efficiently separating copper ore from molybdenum ore. The ore dressing method is provided with: a conditioning step for adding a sulfite as a surface treatment agent to an ore slurry comprising copper ore and molybdenum ore; and after the conditioning step, an ore flotation step for performing ore flotation using the ore slurry. By selectively increasing the hydrophilicity of the copper ore with the sulfite, it is possible to impart a difference in hydrophilicity between the copper ore and the molybdenum ore. As a result, it is possible to selectively cause the molybdenum ore to float and to separate the copper ore from the molybdenum ore efficiently.

IPC Classes  ?

• C22B 1/00 - Preliminary treatment of ores or scrap
• B03D 1/002 - Inorganic compounds
• C22B 15/00 - Obtaining copper
• C22B 34/34 - Obtaining molybdenum

Abstract

[Problem] The present invention addresses the problem of developing a method for controlling a target RNA. [Solution] Provided is a fusion protein containing: a functional domain that improves the protein expression from mRNA; and a PPR protein capable of selectively binding RNA bases or specifically binding an RNA base sequence, with respect to a target mRNA.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C07K 14/435 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• C12N 15/09 - Recombinant DNA-technology

Abstract

A medicine for preventing and/or treating multiple sclerosis, particularly pain such as neuropathic pain associated with multiple sclerosis and the like, said medicine containing, as an active ingredient, a compound having an antagonistic activity on P2X4 receptors, e.g., a compound represented by general formula (IH), or a salt of the compound, or a hydrate or solvate of the compound or the salt.

IPC Classes  ?

• A61K 31/5513 - 1,4-Benzodiazepines, e.g. diazepam
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention addresses the problem of providing a method for differentiating primordial germ cells into functionally mature GV stage oocytes by in vitro culture. The present invention pertains to a method for differentiating primordial germ cells into functional GV stage oocytes in vitro including (a) a step for forming secondary follicles by culturing primordial germ cells and feeder cells adjacent to the primordial germ cells under conditions that eliminate the effects of estrogen or factors having a similar function to estrogen, (b) a step for partially cleaving the bonds between the granulosa cell layer and the thecal cell layer among the oocyte, granulosa cell layer, and thecal cell layer that constitute the formed secondary follicles, and (c) a step for differentiating the oocytes into functional GV stage oocytes by culturing the oocytes and granulosa cell layer that constitute the secondary follicles and the thecal cell layer in medium including a polymer compound.

IPC Classes  ?

• C12N 5/075 - Oocytes; Oogonia
• C12N 5/0735 - Embryonic stem cells; Embryonic germ cells
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided is a system for efficiently recovering trace metal from a large amount of a raw material, such as when trace metal is recovered from nickel oxide ore. This ion exchange resin has, on a carrier, an amide derivative represented by the following general formula. In the formula, R1 and R2 represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R1 represents a hydrogen atom or an arbitrary group, other than an amino group, bonded to a carbon as an amino acid. The amide derivative is preferably a glycineamide derivative. The carrier preferebly includes a primary amine and/or a secondary amino.

IPC Classes  ?

• B01J 45/00 - Ion-exchange in which a complex or a chelate is formed; Use of material as complex or chelate forming ion-exchangers; Treatment of material for improving the complex or chelate forming ion-exchange properties
• B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
• C22B 3/06 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in inorganic acid solutions
• C22B 3/42 - Treatment or purification of solutions, e.g. obtained by leaching by ion-exchange extraction

Abstract

The present invention relates to a compound represented by general formula (II) having a P2X4 receptor antagonist action. (II) (In the formula, R1a to R6a are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, etc., Xa is C or N, and Ya is N or C (=O), provided that when Xa is C, Ya is N, and when Xa is N, Ya is C (=O), a dual line consisting of solid and broken lines is a single bond or a double bond, Aa is a benzene ring, a pyridine ring, etc., Da is a tetrazole ring, an imidazole ring, etc., Ea is -(CR9aR10a)p-Ta-, and Ga is a benzene ring, a pyridine ring, etc.)

IPC Classes  ?

• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 403/08 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing alicyclic rings

Abstract

The present invention relates to a compound represented by general formula (I) having a P2X4 receptor antagonist action. (I) (In the formula, R1, R2 and R3 are a hydrogen atom, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a halogen atom, etc., X is C or N, and Y is N or C (=O), provided that when X is C, Y is N, and when X is N, Y is C (=O), a dual line consisting of solid and broken lines is a single bond or a double bond, n is an integer of 0 to 6, Z is O, S or a bond, and A is a benzene ring, a pyridine ring, etc.)

IPC Classes  ?

• C07D 243/10 - Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

[Problem] Based on the prediction that the rules for DNA recognition possessed by a PPR motif may also be used in DNA recognition, perform analysis of PPR protein that is active in DNA binding, and search for a PPR protein that has such characteristics. The present invention addresses the aforementioned problem by means of a protein that can bind DNA base-selectively or DNA base sequence-specifically, and that contains a plurality of, preferably 2-30, more preferably 5-25, and even more preferably 9-15, PPR motifs having the structure in formula 1 (in formula 1: Helix A is a part that can form an a helix structure; X is a part that does not exist or that comprises 1-9 amino acids; Helix B is a part that can form an a helix structure; and L is a part that comprises 2-7 amino acids), the PPR motif having a specific combination of three amino acids corresponding to the DNA base or target base sequence: first A.A. of Helix A and the 4th A.A. of Helix A in formula 1, together with the "ii"(-2)th A.A. contained in L. (Helix A)-X-(Helix B)-L (formula 1)

IPC Classes  ?

• C07K 4/10 - Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from plants
• C12Q 1/6804 - Nucleic acid analysis using immunogens
• C12Q 1/6811 - Selection methods for production or design of target specific oligonucleotides or binding molecules
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C07K 19/00 - Hybrid peptides
• C12N 9/22 - Ribonucleases

Abstract

The present invention extracts precious metals from an acidic solution containing precious metals in an early and highly efficient manner. Provided is an extraction agent for precious metals that is represented by the general formula below. In the formula, R1 and R2 each represent the same alkyl group or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a discretionary group that is not an amino group and that bonds to a carbon as an amino acid. It is preferable that the general formula have a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit (see above formula)

IPC Classes  ?

• C22B 11/00 - Obtaining noble metals
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds

Abstract

In order to selectively extract copper and/or lead from an acidic solution containing high concentrations of manganese, etc., the valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, R1 and R2 each represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an a carbon as an amino acid. In general formula (1), the inclusion of a glycine unit, a histidine unit, a lysine unit, an asparagine acid unit, or a normal methylglycine unit is preferred. When using the extracting agent to extract copper/and lead, it is preferable that the pH of the acidic solution be adjusted to 1.0-5.5 inclusive.

IPC Classes  ?

• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 13/00 - Obtaining lead
• C22B 15/00 - Obtaining copper

Abstract

Provided is a method for efficiently separating nickel, cobalt and/or scandium, and impurities from an acidic solution containing impurities such as manganese, iron, zinc, and aluminum. A valuable-metal extracting agent of the present invention is expressed by general formula (1). In the formula, R1 and R2 each represent the same or different alkyl groups, R3 represents a hydrogen atom or an alkyl group, and R4 represents a hydrogen atom or a given group, other than an amino group, that bonds with an a carbon as an amino acid. In general formula (1), the inclusion of a glycine unit, a histidine unit, a lysine unit, an asparagine acid unit, or a normal methylglycine unit is preferred. (see above formula)

IPC Classes  ?

• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 23/00 - Obtaining nickel or cobalt
• C22B 59/00 - Obtaining rare earth metals

Abstract

In the present invention, nickel is selectively extracted from an acidic solution that contains a high concentration of manganese. This valuable metal extraction agent is represented by the general formula. In the formula, R1 and R2 are alkyl groups that may be the same or different, R3 is a hydrogen atom or an alkyl group, and R4 is a hydrogen atom or any group, other than an amino group, bonded to an a carbon atom of an amino acid. The general formula preferably has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit or a n-methylglycine unit. When extracting nickel by using this extraction agent, it is preferable to adjust the pH of the acidic solution to 2.3 to 5.5 inclusive.

IPC Classes  ?

• C22B 23/00 - Obtaining nickel or cobalt
• B01D 11/04 - Solvent extraction of solutions which are liquid
• C07C 237/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61P 7/12 - Antidiuretics, e.g. drugs for diabetes insipidus
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor

Abstract

The objective of the present invention is to selectively extract cobalt from an acidic solution containing a high concentration of manganese. This cobalt extraction method extracts cobalt from an acidic solution containing manganese and cobalt by subjecting the acidic solution to solvent extraction by means of a valuable metal extraction agent comprising an amide derivative represented by general formula (I). The valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each represent the same or different alkyl group; R3 represents a hydrogen atom or an alkyl group; and R4 represents a hydrogen atom or any given group aside from an amino group bonded to the a carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, the pH of the acidic solution is 3.5-5.5 inclusive.

IPC Classes  ?

• C22B 3/32 - Carboxylic acids
• C22B 23/00 - Obtaining nickel or cobalt
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

The objective of the present invention is to selectively extract light rare earth metals, and by extension, europium, from an acidic solution containing a plurality of types of rare earth metal. This valuable metal extraction agent is represented by the general formula. In the formula: R1 and R2 each indicate the same or different alkyl group; R3 indicates a hydrogen atom or an alkyl group; and R4 indicates a hydrogen atom or any given group other than an amino group bonded to the a carbon as an amino acid. Preferably, the general formula has a glycine unit, a histidine unit, a lysine unit, an aspartic acid unit, or an N-methylglycine unit. Preferably, when extracting europium using the extraction agent, the pH is adjusted into the range of 2.0-3.0 inclusive, and when selectively extracting light rare earth metals, the pH is adjusted to 1.7-2.7 inclusive. (see above formula)

IPC Classes  ?

• C22B 3/32 - Carboxylic acids
• C22B 59/00 - Obtaining rare earth metals
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

A P2X4 receptor antagonist such as paroxetine, a diazepinedione derivative having the following formula (IX) is used as an agent for preventing or treating neuropathic pain associated with Guillain-Barre syndrome: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring. (see above formula)

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/04 - Centrally acting analgesics, e.g. opioids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A P2X4 receptor antagonist such as paroxetine, a di- azepinedione derivative having the following formula (IX) is used as an agent for preventing or treating zoster- associated pain in acute phase: wherein R1 is hydrogen, a C1-8 alkyl group, or the like; each of R2 and R3 is hydrogen, a C1-8 alkyl group, or the like; each of R4 and R5 is hydrogen or the like; and W is a five-membered or six-membered heterocyclic ring optionally having one or more substituents and comprising one to four nitrogen atoms as the members of the ring.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

[Problem] To provide a transformation method for producing a stramenopile organism having an improved unsaturated fatty acid production capability by disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner. [Solution] A method for transforming a stramenopile organism, which comprises disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner, and which is characterized in that the stramenopile organism is selected from Thraustochytrium aureum, Parietichytrium sarkarianum, Thraustochytrium roseum and Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.

IPC Classes  ?

• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/13 - Unicellular algae; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 9/10 - Transferases (2.)
• C12N 15/09 - Recombinant DNA-technology

Abstract

A method of detecting space debris includes generating a virtual space debris piece in accordance with the law of conservation of mass by applying a debris breakup model to an object of breakup origin which is likely to have broken up on a geocentric orbit in the past (steps 1 and 3) , calculating an orbit of each virtual space debris piece during fixed point observation by applying a debris orbit propagation model to the virtual space debris piece (step 55) , and generating appearance frequency distribution of a motion vector of each virtual space debris piece on the celestial sphere on the basis of a result of the orbit calculation (step S13) . The series of the above steps are executed multiple times (step S9, step S11) . The method further includes setting a search range vector on the basis of a motion vector having a high level of the appearance frequency distribution. of the motion vector, and applying a stacking method to regions in images captured at time intervals during the fixed point observation, the regions being shifted along the search range vector sequentially in the order of capture, thereby detecting space debris appearing on the images (steps S17 to S21).

IPC Classes  ?

• B64G 3/00 - Observing or tracking cosmonautic vehicles
• B64G 1/68 - Arrangements or adaptations of apparatus or instruments, not otherwise provided for of meteoroid or space debris detectors
• G06T 7/20 - Analysis of motion

Abstract

The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three- dimensional structure thereof and exhibits higher effector activity such as an antibody- dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. In addition, the present invention provides an anti-human TIM-3 antibody having high ADCC activity by screening an anti-human TIM-3 antibody which competes with the monoclonal antibody or the antibody fragment thereof.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• C12N 15/13 - Immunoglobulins
• C12P 21/08 - Monoclonal antibodies
• G01N 33/577 - Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies

Abstract

Disclosed is a transformation method whereby an ability to produce a useful substance of a stramenopile can be improved. The method for transforming a stramenopile comprises transferring a foreign gene into the stramenopile which is a microorganism belonging to the class Labyrinthula, more specifically, to a genus Labyrinthula, Altornia, Aplanochytrium, Schizochytrium, Aurantiochytrium, Thraustochytrium, Ulkenia, etc. Said foreign gene, which is a gene relating to tolerance against an antibiotic, a colorimetric protein and/or a fatty acid desaturase (?5 desaturase gene, ?12 desaturase gene and/or ?3 desaturase gene), is transferred by using the electroporation or gene-gun technique.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• A23D 9/00 - Other edible oils or fats, e.g. shortenings, cooking oils
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 35/66 - Microorganisms or materials therefrom
• C11B 1/00 - Production of fats or fatty oils from raw materials
• C11C 3/00 - Fats, oils or fatty acids obtained by chemical modification of fats, oils or fatty acids, e.g. by ozonolysis
• C12N 1/00 - Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
• C12N 1/11 - Protozoa; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/13 - Unicellular algae; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/53 - Oxidoreductases (1)
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

Electrode active material that is used together with an electrolyte solution having an electrolyte decomposition potential Ve is represented by the general expression LixFeMyO2 and is amorphous. In the expression, x and y are values which independently satisfy 1 < x <= 2.5 and O < y <= 3, respectively, and z = (x + (valence of Fe) + (valence of M) x y) / 2 to satisfy stoichiometry, and M represents one or two or more types of glass former element. The average electronegativity of M is less than (Ve + 6.74 / 5.41.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids

Abstract

There are provided positive electrode active materials that consist essentially of an olivine-type lithium manganese phosphate compound particles represented by the following general formula (2) Li x Mn y M1z M2 w PO4 (2) wherein 0 < x < 2, 0 < y < 1, 0 < z < 0.2, 0 < w < 0.2, M1 is at least one divalent metal element selected from the group consisting of Co, Ni, and Fe, and M2 is Ti; and carbon on the surface of the olivine-type lithium manganese phosphate compound particles in an amount no greater than 20 weight% wherein said positive electrode active material has a particle diameter of 10 to 500 nm. There are also provided methods of producing such positive electrode active materials.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators
• C01B 25/45 - Phosphates containing plural metal, or metal and ammonium
• H01M 4/04 - Processes of manufacture in general

Abstract

The present invention provides a positive electrode active material that has rate characteristics suitable for nonaqueous electrolyte batteries and particularly nonaqueous electrolyte secondary batteries, a method by which this positive electrode active material can be easily mass produced, and a high-performance nonaqueous electrolyte battery that has a positive electrode active material obtained by this method. The present invention relates to a method of producing a positive electrode active material, the method comprising a step of mixing a carbon source with lithium manganese phosphate LiMnPO4 or a compound LiMn1-x M x PO4 (where, 0 <= x < 1 and M is at least one metal element selected from the group consisting of Co, Ni, Fe, Zn, Cu, Ti, Sn, Zr, V, and Al) containing lithium manganese phosphate LiMnPO4 as a solid solution composition, and heat treating the obtained mixture under an inert gas atmosphere.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators

Abstract

There is disclosed a bone substitute material for medical use which satisfies all the requirements of (1) no histotoxicity, (2) osteoconductivity, (3) bone replacement capability, and (4) mechanical strength necessary for a bone reconstruction operation. The bone substitute material for medical use is predominantly composed of carbonate apatite and produced through the formation of carbonate apatite by contacting a block of calcium compound with a phosphate-containing solution, wherein the calcium compound block contains substantially no powders, and at least one of said calcium compound block and said phosphate solution contains a carbonate group, without any sintering. The block of calcium compound is preferably one prepared using an artificially synthesized calcium compound, most preferably a foamed calcium compound.

IPC Classes  ?

• A61L 27/12 - Phosphorus-containing materials, e.g. apatite